1. Home
  2. MRCC vs LCTX Comparison

MRCC vs LCTX Comparison

Compare MRCC & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRCC
  • LCTX
  • Stock Information
  • Founded
  • MRCC 2011
  • LCTX 1990
  • Country
  • MRCC United States
  • LCTX United States
  • Employees
  • MRCC N/A
  • LCTX N/A
  • Industry
  • MRCC Investment Managers
  • LCTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • MRCC Finance
  • LCTX Health Care
  • Exchange
  • MRCC Nasdaq
  • LCTX Nasdaq
  • Market Cap
  • MRCC 174.8M
  • LCTX 110.2M
  • IPO Year
  • MRCC 2012
  • LCTX N/A
  • Fundamental
  • Price
  • MRCC $8.24
  • LCTX $0.55
  • Analyst Decision
  • MRCC Strong Buy
  • LCTX Strong Buy
  • Analyst Count
  • MRCC 1
  • LCTX 5
  • Target Price
  • MRCC $9.00
  • LCTX $4.80
  • AVG Volume (30 Days)
  • MRCC 65.9K
  • LCTX 2.9M
  • Earning Date
  • MRCC 11-12-2024
  • LCTX 03-06-2025
  • Dividend Yield
  • MRCC 12.14%
  • LCTX N/A
  • EPS Growth
  • MRCC 298.01
  • LCTX N/A
  • EPS
  • MRCC 0.60
  • LCTX N/A
  • Revenue
  • MRCC $62,007,000.00
  • LCTX $8,719,000.00
  • Revenue This Year
  • MRCC N/A
  • LCTX N/A
  • Revenue Next Year
  • MRCC N/A
  • LCTX $41.15
  • P/E Ratio
  • MRCC $13.73
  • LCTX N/A
  • Revenue Growth
  • MRCC N/A
  • LCTX N/A
  • 52 Week Low
  • MRCC $6.97
  • LCTX $0.48
  • 52 Week High
  • MRCC $8.80
  • LCTX $1.61
  • Technical
  • Relative Strength Index (RSI)
  • MRCC 46.26
  • LCTX 47.26
  • Support Level
  • MRCC $8.10
  • LCTX $0.51
  • Resistance Level
  • MRCC $8.80
  • LCTX $0.60
  • Average True Range (ATR)
  • MRCC 0.21
  • LCTX 0.04
  • MACD
  • MRCC -0.02
  • LCTX 0.01
  • Stochastic Oscillator
  • MRCC 23.29
  • LCTX 53.85

About MRCC Monroe Capital Corporation

Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Share on Social Networks: